Related Experiment Video
Updated: Jul 27, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Percutaneous nephrolithotomy during uninterrupted aspirin therapy in high-cardiovascular risk patients: preliminary
David A Leavitt1, Nithin Theckumparampil1, Daniel M Moreira1
1The Arthur Smith Institute for Urology, Hofstra North Shore-Long Island Jewish School of Medicine, New Hyde Park, NY.
Insights
Percutaneous nephrolithotomy (PCNL) is safe for high-cardiovascular risk patients on aspirin. This kidney stone treatment showed low complication rates and no major adverse events, making it a viable option.
Area of Science:
- Urology
- Nephrology
- Cardiology
Background:
- High-cardiovascular risk patients often require antiplatelet therapy like aspirin.
- Discontinuing aspirin can increase the risk of thromboembolic events.
- Percutaneous nephrolithotomy (PCNL) is a common procedure for large kidney stones.
Purpose of the Study:
- To assess the feasibility and safety of performing PCNL in patients who continue aspirin therapy.
- To evaluate surgical outcomes and the incidence of thromboembolic events in this patient group.
Main Methods:
- Retrospective review of 16 PCNL procedures performed between July 2012 and January 2014.
- Patients included were on uninterrupted aspirin therapy for imperative indications.
- Evaluation of surgical outcomes, complications, and thromboembolic events.
Main Results:
- 16 PCNL procedures were performed in 14 high-cardiovascular risk patients on aspirin.
- Mean surgery time was 66 minutes, with mean blood loss of 161 mL.
- No intraoperative complications or perioperative thromboembolic/cardiac events occurred. Postoperative complications included 4 Clavien grade II and 1 grade IIIa. Three patients required transfusion; no delayed bleeding.
- All patients achieved stone-free status.
Conclusions:
- PCNL can be safely and effectively performed in high-cardiovascular risk patients continuing aspirin.
- The procedure is associated with an acceptably low transfusion rate compared to the risks of thromboembolic events.
- PCNL is a viable treatment option for large renal stones in patients on aspirin therapy.
Objective:
To determine the feasibility and safety of performing percutaneous nephrolithotomy (PCNL) in high-cardiovascular risk patients remaining on aspirin therapy.
Methods:
We retrospectively reviewed all PCNLs performed by 3 fellowship-trained endourologists at a single institution between July 2012 and January 2014. All patients remaining on aspirin for imperative indications through the day of surgery were evaluated for surgical outcomes and thromboembolic events.
Results:
Of 281 PCNL procedures performed during the study period, 16 (5.7%) were performed in 14 patients taking aspirin, uninterrupted, through surgery. Mean surgery time was 66 minutes, mean estimated blood loss was 161 mL, and mean length of hospital stay was 2.8 days. All patients were stone free. There were no intraoperative complications. A total of 5 patients experienced a postoperative complication (n = 4, Clavien grade II; n = 1, Clavien grade IIIa). No patient experienced a perioperative thromboembolic or cardiac event. Three patients required a blood transfusion postoperatively, and none experienced delayed renal bleeding.
Conclusion:
PCNL can be performed safely and effectively in high-cardiovascular risk patients continuing aspirin perioperatively. Compared with the potential sequelae of a thromboembolic or cardiac event, PCNL is associated with an acceptably low transfusion rate, and should be considered a viable treatment option for large renal stones in this population.
Related Concept Videos
Cardiac Catheterization I: Pre-Procedure Overview
Cardiac Catheterization IV: Nursing Management
Urinary Tract Calculi VI: Surgical Management
Imaging Studies V: Intravenous Urography and Retrograde Pyelography
Imaging Studies VII: Vascular Imaging
Acute Kidney Injury IV: Diagnostic Studies and Prevention
